BEXSERO®

BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO

...continue reading

An Important Gap in Meningococcal Disease Protection*

Until late 2014, you have only been able to help protect your patients against 4 (A,C, W-135, Y) of the 5 vaccine-preventable serogroups historically responsible for the majority of meningococcal disease."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"[3,5,9]

Between 99 and 188 cases of meningococcal group B disease occurred annually in patients <1 to ≥65 years of age in the US between 2008 and 2013 (0.03-0.06/100,000 population)."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"[1] Up to 1 in 5 survivors of meningococcal disease will suffer from sequelae."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"[2]

* Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains.
Includes serogroup W-135 and nongroupable serotypes.

Meningococcal Disease Is Rare, but Fast-moving, and Potentially Fatal

While the incidence in the US is low, the consequences may be serious."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"[1,2]

One in 10 people diagnosed with meningococcal disease dies, some within 24 HOURS of symptoms onset."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"[6]

Because early symptoms of meningococcal disease can resemble the flu, appropriate and potentially life-saving treatment options may be delayed."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"[2,6]

Estimated case fatality rate in the US is 10%-15%."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"[3]

References

"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"View all references

709301R0 May 2016